EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Early initiation of intravenous cyclophosphamide and one‐year outcome in super‐refractory cryptogenic‐new onset refractory status epilepticus

Yasufumi Yorichika iD, Shuichiro Neshige iD, Hideaki Sakahara, Narumi Ono, Megumi Nonaka iD, Yuichiro Tagane, Tomoaki Watanabe, Keisuke Tachiyama, Haruka Ishibashi, Masahiro Nakamori, Takeo Shishido, Shiro Aoki iD und 4 weitere

Epilepsia Open · 2025

DOI: 10.1002/epi4.13055 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Epilepsia Open, 2025. Verfasst von Yasufumi Yorichika und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan. Hauptthemen laut MEDLINE: Cyclophosphamide, Status Epilepticus, Drug Resistant Epilepsy, Immunosuppressive Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To explore the potential efficacy of early initiation of intravenous cyclophosphamide (IVCPA), we reviewed consecutive four cases of super‐refractory cryptogenic‐new onset refractory status epilepticus (C‐NORSE) between 2015 and 2023. We compared functional outcomes at 3 months and 1 year after the onset between patients who received IVCPA within 20 days (early‐treated) and those who received it later (late‐treated). All patients (median age: 43 years) had a prodromal fever. Brain MRI revealed symmetrically increased FLAIR signals in the medial temporal lobes of all patients. Despite initiating antiseizure medications (ASMs) and first‐line immunotherapy (intravenous‐methylprednisolone and immunoglobulins) within a median of 3 days from onset, SE persisted >5 days. The diagnosis of C‐NORSE was suggested based on a high C‐NORSE score (6/6). Thus, all patients received IVCPA a median of 15.5 days after seizure onset (three within 20 days and one at 31 days). One of the three early‐treated patients also received tocilizumab. Early‐treated patients exhibited shorter sedation periods (median 29 vs. 75 days) and better 1 year functional status (mRS 1–2 vs. mRS 4) compared to the late‐treated patient. Early initiation of IVCPA and/or tocilizumab, along with ASMs, may contribute to a better one‐year functional status in super‐refractory C‐NORSE patients. Plain Language Summary This study demonstrates the potential efficacy of early administration of intravenous cyclophosphamide on one‐year functional status in patients with super‐refractory cryptogenic‐new onset refractory status epilepticus. “Early‐treated patients” who received it within 20 days of seizure onset achieved a good one‐year functional status. The “late‐treated patient” (Case 4) who received it later did not achieve a good functional status. Early initiation of cyclophosphamide, along with antiseizure medications, may contribute to a better one‐year functional status in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CyclophosphamideStatus EpilepticusDrug Resistant EpilepsyImmunosuppressive AgentsHumansAdultMaleFemaleMiddle AgedTreatment OutcomeAdministration, IntravenousMagnetic Resonance ImagingAnticonvulsants

Stichwörter der Autor:innen

NORSEautoantibodiesbrain MRIimmunotherapy

Substanzen

CyclophosphamideImmunosuppressive AgentsAnticonvulsants

Autor:innen und Institutionen

  • Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan.
  • Epilepsy Center, Hiroshima University Hospital, Hiroshima, Japan.
  • Department of Neurology, Hiroshima North Medical Center Asa Citizens Hospital, Hiroshima, Japan.
  • Department of Neurology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
  • Department of Neurology, Kitasato University School of Medicine, Sagamihara, Japan.

ORCID-Profile: Yasufumi Yorichika, Shuichiro Neshige, Megumi Nonaka, Shiro Aoki, Takahiro Iizuka

Zitieren

APA

Yorichika, Y., Neshige, S., Sakahara, H., Ono, N., Nonaka, M., Tagane, Y., Watanabe, T., Tachiyama, K., Ishibashi, H., Nakamori, M., Shishido, T., Aoki, S., Ueno, H., Yamazaki, Y., Iizuka, T., & Maruyama, H. (2025). Early initiation of intravenous cyclophosphamide and one‐year outcome in super‐refractory cryptogenic‐new onset refractory status epilepticus. Epilepsia Open. https://doi.org/10.1002/epi4.13055

Vancouver

Yorichika Y, Neshige S, Sakahara H, Ono N, Nonaka M, Tagane Y, et al. Early initiation of intravenous cyclophosphamide and one‐year outcome in super‐refractory cryptogenic‐new onset refractory status epilepticus. Epilepsia Open. 2025. doi:10.1002/epi4.13055

BibTeX
@article{Yorichika2025,
  author = {Yorichika, Yasufumi and Neshige, Shuichiro and Sakahara, Hideaki and Ono, Narumi and Nonaka, Megumi and Tagane, Yuichiro and Watanabe, Tomoaki and Tachiyama, Keisuke and Ishibashi, Haruka and Nakamori, Masahiro and Shishido, Takeo and Aoki, Shiro and Ueno, Hiroki and Yamazaki, Yu and Iizuka, Takahiro and Maruyama, Hirofumi},
  title = {Early initiation of intravenous cyclophosphamide and one‐year outcome in super‐refractory cryptogenic‐new onset refractory status epilepticus},
  journal = {Epilepsia Open},
  year = {2025},
  doi = {10.1002/epi4.13055}
}
Kostenlos starten →